 Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-19 patients EBRIS will advance larazotide into an Australian Investigational New Drug Phase 1 study expected to begin in 2021 RALEIGH, NC and SALERNO, ITALY ACCESSWIRE December 21, 2020 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage rare and unmet needs-focused gastroenterology company, today announced a collaboration with the European Biomedical Research Institute of Salerno EBRIS, to advance to a study in order to evaluate the safety and tolerability of larazotide when delivered to lung tissue in healthy volunteers. Larazotide, a first-in-class tight junction modulator, is hypothesized to act on lung endothelial cells. 